AZD3965 is primarily investigated for its potential in cancer therapy, particularly targeting cancers that rely on aerobic glycolysis, a phenomenon known as the Warburg effect. It functions as a monocarboxylate transporter 1 (MCT1) inhibitor, which plays a crucial role in the transport of lactate across cell membranes. By inhibiting MCT1, AZD3965 disrupts the lactate efflux from cancer cells, leading to an accumulation of lactate intracellularly. This accumulation can alter the pH balance within cancer cells, potentially inducing cell death and inhibiting tumor growth. Its application is especially promising in cancers that are highly glycolytic and express high levels of MCT1, such as certain types of lymphomas and solid tumors. Clinical trials are ongoing to evaluate its efficacy and safety in treating these cancers, with the hope of providing a new therapeutic option for patients with limited treatment alternatives.